The Life Sciences team advised Teva Pharmaceutical Industries Ltd. as it closed two definitive agreements to sell the remaining assets of its specialty global women’s health business for $1.38 billion. Proceeds from these sales, combined with proceeds from the sale of PARAGARD®, on which Goodwin also advised Teva, total $2.48 billion and will be used by Teva to progress repayment of term loan debt.
- On February 1, Teva closed its agreement under which CVC Capital Partners Fund VI acquired a portfolio of products within Teva’s global women’s health business across contraception, fertility, menopause and osteoporosis for $703 million in cash. The Goodwin team was led by partners David Henken, Robert Crawford and Gregg Katz; and associates Melissa Paddock, Jennifer Ford, Emily Beman, Peter Hanoian and trainee Priya Patel.
- On November 2, 2017, Teva closed its agreement under which Foundation Consumer Healthcare acquired Plan B One-Step® and Teva’s value brands of emergency contraception, Take Action®, Aftera® and Next Choice One Dose® for $675 million in cash. The Goodwin team was led by partners David Henken, Robert Crawford, Gregg Katz, Ed Amer, John Mutkoski and Kingsley Taft and included partners Milena Tantcheva and James Matarese; counsel Kirby Lewis; and associates Jennifer Ford, Emily Beman, Peter Hanoian, Sarah Smith, Catherine Magazu and Chloe Pletner.
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in over 60 markets every day.